Organ Transplantation Research Today is a free monthly online journal that collates and summarizes the latest research about Organ Transplantation, including details on risks, prognosis, procedure, surgery.

Volume 2 (2005), Issue 4 (April)

1. An in vivo study of a bone grafting material consisting of hydroxyapatite and reconstituted collagen.
   J Mater Sci Mater Med, 16(4): 341-5. [Abstract] [Full-text]
2. Pneumonia in the solid organ transplant patient.
   Clin Chest Med, 26(1): 113-21. [Abstract] [Full-text]
3. Living donor liver transplantation: the historical and cultural basis of policy decisions and ongoing ethical questions.
   Health Policy, 72(2): 175-85. [Abstract] [Full-text]
4. Is noncompliance among adolescent renal transplant recipients inevitable?
   Pediatrics, 115(4): 969-73. [Abstract] [Full-text]
5. The use of structural distal femoral allografts for acetabular reconstruction. Average ten-year follow-up.
   J Bone Joint Surg Am, 87(4): 760-5. [Abstract] [Full-text]
6. Osteonecrosis of the femoral head. A study of 101 hips treated with vascularized fibular grafting.
   J Bone Joint Surg Am, 87(4): 742-7. [Abstract] [Full-text]
7. Atypical radiological presentation of progressive multifocal leukoencephalopathy following liver transplantation.
   J Neurovirol, 11(1): 46-50. [Abstract] [Full-text]
8. Surgical transplant physical examination: correlation of renal resistance index and biopsy-proven chronic allograft nephropathy.
   J Am Coll Surg, 200(4): 552-6. [Abstract] [Full-text]
9. Kidney transplantation under minimal immunosuppression after pretransplant lymphoid depletion with Thymoglobulin or Campath.
   J Am Coll Surg, 200(4): 505-15; quiz A59-61. [Abstract] [Full-text]
10. Manifestation of atopic eczema in children after heart transplantation in the first year of life.
    Pediatr Dermatol, 22(2): 102-8. [Abstract] [Full-text]
11. No effect of platelet-rich plasma with frozen or processed bone allograft around noncemented implants.
    Int Orthop, 29(2): 67-72. [Abstract] [Full-text]
12. Recruitment of Foxp3+ T regulatory cells mediating allograft tolerance depends on the CCR4 chemokine receptor.
    J Exp Med, 201(7): 1037-44. [Abstract] [Full-text]
13. Improving outcomes in heart transplantation: the potential of proliferation signal inhibitors.
    Transplant Proc, 37(4): 4S-17S. [Abstract] [Full-text]
14. Effect of kidney transplantation on left ventricular systolic dysfunction and congestive heart failure in patients with end-stage renal disease.
    J Am Coll Cardiol, 45(7): 1051-60. [Abstract] [Full-text]
15. The effects of renal transplantation on circulating dendritic cells.
    Clin Exp Immunol, 140(2): 384-93. [Abstract] [Full-text]
16. Co-stimulation blockade targeting CD154 and CD28/B7 modulates the induced antibody response after a pig-to-baboon cardiac xenograft.
    Xenotransplantation, 12(3): 197-208. [Abstract] [Full-text]
17. Primary cutaneous cryptococcal cellulitis secondary to insect bite in an immunosupressed patient after liver transplantation.
    Clin Exp Dermatol, 30(3): 241-3. [Abstract] [Full-text]
18. Protection from cytomegalovirus after transplantation is correlated with immediate early 1-specific CD8 T cells.
    J Exp Med, 201(7): 1031-6. [Abstract] [Full-text]
19. Morphological and biochemical characterization of a human liver in a uPA-SCID mouse chimera.
    Hepatology, 41(4): 847-56. [Abstract] [Full-text]
20. Hepatitis B and C virus variants in long-term immunosuppressed renal transplant patients in Latvia.
    Intervirology, 48(2): 192-200. [Abstract] [Full-text]
21. Vasopressor administration during liver transplant surgery and its effect on endotracheal reintubation rate in the postoperative period: a prospective, randomized, double-blind, placebo-controlled trial.
    Clin Ther, 27(2): 192-8. [Abstract] [Full-text]
22. Subcutaneous panniculitic T-cell lymphoma in a cardiac allograft recipient.
    J Cutan Pathol, 32(5): 366-70. [Abstract] [Full-text]
23. Morphometric analysis of primary graft non-function in liver transplantation.
    Histopathology, 46(4): 451-9. [Abstract] [Full-text]
24. Orthopaedic manifestations of the hip in haemophilia--impaction bone grafting used in revision total hip arthroplasty in a haemophilic patient.
    Haemophilia, 11(2): 175-7. [Abstract] [Full-text]
25. Pediatric cardiac transplants: a clinical update.
    J Pediatr Nurs, 20(2): 139-43. [Abstract] [Full-text]
26. Spectrum of surgical complications after simultaneous pancreas-kidney transplantation in a prospectively randomized study of two immunosuppressive protocols.
    Nephrol Dial Transplant, 20: ii54-62. [Abstract] [Full-text]
27. Impact of HLA matching on the outcome of simultaneous pancreas-kidney transplantation.
    Nephrol Dial Transplant, 20: ii48-53, ii62. [Abstract] [Full-text]
28. A large, prospective, randomized, open-label, multicentre study of corticosteroid withdrawal in SPK transplantation: a 3-year report.
    Nephrol Dial Transplant, 20: ii40-7, ii62. [Abstract] [Full-text]
29. Secondary effects of immunosuppressive drugs after simultaneous pancreas-kidney transplantation.
    Nephrol Dial Transplant, 20: ii33-9, ii62. [Abstract] [Full-text]
30. Efficacy and safety of tacrolimus compared with cyclosporin microemulsion in primary SPK transplantation: 3-year results of the Euro-SPK 001 trial.
    Nephrol Dial Transplant, 20: ii3-10, ii62. [Abstract] [Full-text]
31. Cytomegalovirus: occurrence, severity, and effect on graft survival in simultaneous pancreas-kidney transplantation.
    Nephrol Dial Transplant, 20: ii25-ii32, ii62. [Abstract] [Full-text]
32. Metabolic results 3 years after simultaneous pancreas-kidney transplantation.
    Nephrol Dial Transplant, 20: ii18-24, ii62. [Abstract] [Full-text]
33. Rejection after simultaneous pancreas-kidney transplantation.
    Nephrol Dial Transplant, 20: ii11-7, ii62. [Abstract] [Full-text]
34. Plasmacytoma of the urinary bladder in a renal transplant recipient.
    Int J Hematol, 81(3): 255-7. [Abstract] [Full-text]
35. Serum analysis after transplant nephrectomy reveals restricted antibody specificity patterns against structurally defined HLA class I mismatches.
    Transpl Immunol, 14(1): 53-62. [Abstract] [Full-text]
36. The cytokine gene polymorphisms in patients with chronic kidney graft rejection.
    Transpl Immunol, 14(1): 49-52. [Abstract] [Full-text]
37. Daclizumab therapy in kidney transplantation-different mechanisms of action in- versus ex-vivo?
    Transpl Immunol, 14(1): 43-7. [Abstract] [Full-text]
38. The impact of pharmacogenomic factors on acute persistent rejection in adult lung transplant patients.
    Transpl Immunol, 14(1): 37-42. [Abstract] [Full-text]
39. Contribution of CD4+ and CD8+ T cells and interferon-gamma to the progress of chronic rejection of kidney allografts: the Th1 response mediates both acute and chronic rejection.
    Transpl Immunol, 14(1): 21-5. [Abstract] [Full-text]
40. Preoperative administration of FTY720 prolonged renal allograft survival.
    Transpl Immunol, 14(1): 1-8. [Abstract] [Full-text]
41. Exogenous melatonin enhances bile flow and ATP levels after cold storage and reperfusion in rat liver: implications for liver transplantation.
    J Pineal Res, 38(4): 223-30. [Abstract] [Full-text]
42. Review article: current management of renal dysfunction in the cirrhotic patient.
    Aliment Pharmacol Ther, 21(8): 949-61. [Abstract] [Full-text]
43. Osteoporosis after solid organ transplantation.
    J Clin Endocrinol Metab, 90(4): 2456-65. [Abstract] [Full-text]
44. Heart transplantation in a 68-year-old patient with senile systemic amyloidosis.
    Am J Transplant, 5(5): 1159-62. [Abstract] [Full-text]
45. Successful outcome of progressive multifocal leukoencephalopathy in a renal transplant patient.
    Am J Transplant, 5(5): 1151-8. [Abstract] [Full-text]
46. Hemolytic uremic syndrome: a fatal outcome after kidney and liver transplantation performed to correct factor h gene mutation.
    Am J Transplant, 5(5): 1146-50. [Abstract] [Full-text]
47. To do or not to do living donor hepatectomy in Jehovah's Witnesses: single institution experience of the first 13 resections.
    Am J Transplant, 5(5): 1141-5. [Abstract] [Full-text]
48. Recrudescent tobacco exposure following heart transplantation: clinical profiles and relationship with athero-thrombosis risk markers.
    Am J Transplant, 5(5): 1137-40. [Abstract] [Full-text]
49. Kidney allograft fibrosis and atrophy early after living donor transplantation.
    Am J Transplant, 5(5): 1130-6. [Abstract] [Full-text]
50. Renal histopathological lesions after orthotopic liver transplantation (OLT).
    Am J Transplant, 5(5): 1120-9. [Abstract] [Full-text]
51. A comparison of tacrolimus and cyclosporine in liver transplantation: effects on renal function and cardiovascular risk status.
    Am J Transplant, 5(5): 1111-9. [Abstract] [Full-text]
52. Hospital-independent organ recovery from deceased donors: a two-year experience.
    Am J Transplant, 5(5): 1105-10. [Abstract] [Full-text]
53. Functional status and quality of life in patients surviving 10 years after lung transplantation.
    Am J Transplant, 5(5): 1099-104. [Abstract] [Full-text]
54. Consequences of eliminating HLA-B in deceased donor kidney allocation to increase minority transplantation.
    Am J Transplant, 5(5): 1090-8. [Abstract] [Full-text]
55. A comparison of long-term graft survival rates between the first and second donor kidney transplanted--the effect of a longer cold ischaemic time for the second kidney.
    Am J Transplant, 5(5): 1071-5. [Abstract] [Full-text]
56. Clinical utility of cytomegalovirus (CMV) serology testing in high-risk CMV D+/R- transplant recipients.
    Am J Transplant, 5(5): 1065-70. [Abstract] [Full-text]
57. Obesity in living kidney donors: clinical characteristics and outcomes in the era of laparoscopic donor nephrectomy.
    Am J Transplant, 5(5): 1057-64. [Abstract] [Full-text]
58. Incidence of C4d stain in protocol biopsies from renal allografts: results from a multicenter trial.
    Am J Transplant, 5(5): 1050-6. [Abstract] [Full-text]
59. Warfarin or low-molecular-weight heparin therapy does not prolong pig-to-primate cardiac xenograft function.
    Am J Transplant, 5(5): 1011-20. [Abstract] [Full-text]
60. Lung preservation: pulmonary flush route affects bronchial mucosal temperature and expression of IFN-gamma and Gro in regional lymph nodes.
    Am J Transplant, 5(5): 995-1001. [Abstract] [Full-text]
61. CTLA4 engagement is required for induction of murine liver transplant spontaneous tolerance.
    Am J Transplant, 5(5): 978-86. [Abstract] [Full-text]
62. Cerebrovascular disease as a complication of cardiac transplantation.
    Cerebrovasc Dis, 19(4): 267-71. [Abstract] [Full-text]
63. Gastric volvulus as a complication of liver transplant.
    Pediatr Radiol, 35(3): 327-9. [Abstract] [Full-text]
64. Recipient intramuscular cotransfection of transforming growth factor beta1 and interleukin 10 ameliorates acute lung graft rejection.
    J Thorac Cardiovasc Surg, 129(4): 926-31. [Abstract] [Full-text]
65. Lung transplantation with lungs from donors fifty years of age and older.
    J Thorac Cardiovasc Surg, 129(4): 919-25. [Abstract] [Full-text]
66. High central venous pressure is associated with prolonged mechanical ventilation and increased mortality after lung transplantation.
    J Thorac Cardiovasc Surg, 129(4): 912-8. [Abstract] [Full-text]
67. Liver transplantation for malignancy.
    Oncologist, 10(4): 269-81. [Abstract] [Full-text]
68. Uretero-neocystostomy in a swine model of kidney transplantation: a new technique.
    J Surg Res, 124(2): 250-5. [Abstract] [Full-text]
69. Effect of exercise training on VO2peak and left ventricular systolic function in recent cardiac transplant recipients.
    Am J Cardiol, 95(8): 1002-4. [Abstract] [Full-text]
70. Aspergillus infections in lung transplant recipients: risk factors and outcome.
    Clin Microbiol Infect, 11(5): 359-65. [Abstract] [Full-text]
71. Effects of pancreas-kidney transplantation on diabetic retinopathy.
    Transpl Int, 18(5): 619-22. [Abstract] [Full-text]
72. Fusarium peritonitis concomitant to kidney transplantation successfully managed with voriconazole: case report and review of the literature.
    Transpl Int, 18(5): 613-8. [Abstract] [Full-text]
73. Role of protein synthesis in the protection conferred by ozone-oxidative-preconditioning in hepatic ischaemia/reperfusion.
    Transpl Int, 18(5): 604-12. [Abstract] [Full-text]
74. Use of different immunosuppressive strategies in recipients of kidneys from nonheart-beating donors.
    Transpl Int, 18(5): 596-603. [Abstract] [Full-text]
75. Immunosuppressive efficacy of mycophenolate mofetil when compared with azathioprine and mizoribine against peripheral lymphocytes from renal transplant recipients.
    Transpl Int, 18(5): 590-5. [Abstract] [Full-text]
76. Assignment of steatotic livers by the Mayo model for end-stage liver disease.
    Transpl Int, 18(5): 577-83. [Abstract] [Full-text]
77. Predictors of death on the waiting list for liver transplantation characterized by a long waiting time.
    Transpl Int, 18(5): 572-6. [Abstract] [Full-text]
78. Bronchoscopy in the diagnosis and surveillance of respiratory infections in lung and heart-lung transplant recipients.
    Transpl Int, 18(5): 562-71. [Abstract] [Full-text]
79. Angioplasty treatment of hepatic vein stenosis in pediatric liver transplants: long-term results.
    Transpl Int, 18(5): 556-61. [Abstract] [Full-text]
80. Differences of perioperative liver function, transfusion, and complications according to the type of hepatectomy in living donors.
    Transpl Int, 18(5): 548-55. [Abstract] [Full-text]
81. Sequential body composition analysis by bioimpedance early post-kidney transplantation.
    Transpl Int, 18(5): 541-7. [Abstract] [Full-text]
82. Prevalence and significance of anti-HLA and donor-specific antibodies long-term after renal transplantation.
    Transpl Int, 18(5): 532-40. [Abstract] [Full-text]
83. Effect of different immunosuppressive therapies on the lipid pattern in kidney-transplanted rats.
    Transpl Int, 18(5): 524-31. [Abstract] [Full-text]
84. Postmortal or living related donor: preferences of kidney patients.
    Transpl Int, 18(5): 519-23. [Abstract] [Full-text]
85. Liver transplantation with preservation of the inferior vena cava in case of symptomatic adult polycystic disease.
    Transpl Int, 18(5): 513-8. [Abstract] [Full-text]
86. Fibrosis and matrix metalloproteinases in rat renal allografts.
    Transpl Int, 18(5): 506-12. [Abstract] [Full-text]
87. Reliability of hepatic artery configuration in 3D CT angiography compared with conventional angiography--special reference to living-related liver transplant donors.
    Transpl Int, 18(5): 499-505. [Abstract] [Full-text]
88. Liver transplantation in alcoholic patients.
    Transpl Int, 18(5): 491-8. [Abstract] [Full-text]
89. Healing properties of allograft from alendronate-treated animal in lumbar spine interbody cage fusion.
    Eur Spine J, 14(3): 222-6. [Abstract] [Full-text]
90. Acute disseminated encephalomyelitis after liver transplantation.
    Arch Neurol, 62(4): 650-2. [Abstract] [Full-text]
91. Successful steroid withdrawal in lung transplant recipients: result of a pilot study.
    Respir Med, 99(5): 596-601. [Abstract] [Full-text]
92. Bilateral subchondral insufficiency fracture of the femoral head after renal transplantation: a case report.
    Arthritis Rheum, 52(4): 1293-6. [Abstract] [Full-text]
93. Post-transplant IVC occlusion and thrombosis treated with tPA, heparin, and sharp recanalization.
    J Gastroenterol, 40(3): 302-5. [Abstract] [Full-text]
94. Splanchnic vein thrombosis in candidates for liver transplantation: usefulness of screening and anticoagulation.
    Gut, 54(5): 691-7. [Abstract] [Full-text]
95. Liver transplantation for hepatocellular carcinoma: is expansion of criteria justified?
    Clin Liver Dis, 9(2): 315-28. [Abstract] [Full-text]
96. Beneficial effect of early initiation of lipid-lowering therapy following renal transplantation.
    Nephrol Dial Transplant, 20(5): 974-80. [Abstract] [Full-text]
97. Efficacy and safety of tacrolimus compared with cyclosporin A microemulsion in renal transplantation: 2 year follow-up results.
    Nephrol Dial Transplant, 20(5): 968-73. [Abstract] [Full-text]
98. Rare cause of ureteral stenosis more than 10 years after kidney transplantation.
    Urology, 65(4): 798. [Abstract] [Full-text]
99. Transplantation and palliative care: the convergence of two seemingly opposite realities.
    Surg Clin North Am, 85(2): 373-82. [Abstract] [Full-text]
100. Evaluation of bone-mineral density by digital X-ray radiogrammetry (DXR) in pediatric renal transplant recipients.
     Pediatr Radiol, 35(5): 489-94. [Abstract] [Full-text]
101. Gallbladder disease in cardiac transplant patients: a survey study.
     Arch Surg, 140(4): 399-403; discussion 404. [Abstract] [Full-text]
102. Twenty-year experience with liver transplantation for hepatocellular carcinoma.
     Arch Surg, 140(4): 353-8. [Abstract] [Full-text]
103. Low-dose retinoids in the prevention of cutaneous squamous cell carcinomas in organ transplant recipients: a 16-year retrospective study.
     Arch Dermatol, 141(4): 456-64. [Abstract] [Full-text]
104. Cutaneous squamous cell carcinoma in organ transplant recipients: a study of the Swedish cohort with regard to tumor site.
     Arch Dermatol, 141(4): 447-51. [Abstract] [Full-text]
105. Rationale and design of the DIRECT study: a comparative assessment of the hyperglycemic effects of tacrolimus and cyclosporine following renal transplantation.
     Contemp Clin Trials, 26(1): 17-24. [Abstract] [Full-text]
106. Pegylated versus standard interferon-alpha in antiviral regimens for post-transplant recurrent hepatitis C: Comparison of tolerability and efficacy.
     J Gastroenterol Hepatol, 20(4): 577-82. [Abstract] [Full-text]
107. Recurrence of migraine with aura due to tacrolimus therapy in a liver transplant recipient successfully treated with sirolimus substitution.
     Headache, 45(3): 245-6. [Abstract] [Full-text]
108. Hypocitraturia as a risk factor for nephrocalcinosis after kidney transplantation.
     Pediatr Nephrol, 20(5): 652-6. [Abstract] [Full-text]
109. Cyclosporine A monitoring--how to account for twice and three times daily dosing.
     Pediatr Nephrol, 20(5): 591-6. [Abstract] [Full-text]
110. Evaluation of the effect of candesartan cilexetil on the steady-state pharmacokinetics of tacrolimus in renal transplant patients.
     Biopharm Drug Dispos, 26(4): 135-41. [Abstract] [Full-text]
111. Sirolimus rescue of renal failure in children after combined liver-kidney transplantation.
     Pediatr Nephrol, 20(5): 686-9. [Abstract] [Full-text]
112. Distinct roles for the kidney and systemic tissues in blood pressure regulation by the renin-angiotensin system.
     J Clin Invest, 115(4): 1092-9. [Abstract] [Full-text]
113. Kidney paired donation and optimizing the use of live donor organs.
     JAMA, 293(15): 1883-90. [Abstract] [Full-text]
114. Insulin resistance, LDL particle size, and LDL susceptibility to oxidation in pediatric kidney and liver recipients.
     Kidney Int, 67(5): 2046-55. [Abstract] [Full-text]
115. A prospective randomized study for prevention of postrenal transplantation bone loss.
     Kidney Int, 67(5): 2039-45. [Abstract] [Full-text]
116. Clinical impact of preexisting vascular calcifications on mortality after renal transplantation.
     Kidney Int, 67(5): 2015-20. [Abstract] [Full-text]
117. Associations between MTHFR 1793G>A and plasma total homocysteine, folate, and vitamin B in kidney transplant recipients.
     Kidney Int, 67(5): 1980-5. [Abstract] [Full-text]
118. Inhibition of the chemokine receptor CXCR2 prevents kidney graft function deterioration due to ischemia/reperfusion.
     Kidney Int, 67(5): 1753-61. [Abstract] [Full-text]
119. Cellular transplantation of nephrons.
     Kidney Int, 67(5): 1677-9. [Abstract] [Full-text]
120. Altered expression of aquaporin-2 in human explants with chronic renal allograft dysfunction.
     BJU Int, 95(7): 1104-8. [Abstract] [Full-text]
121. Long-term outcome in relation to renal sympathetic activity in patients with chronic heart failure.
     Eur Heart J, 26(9): 906-13. [Abstract] [Full-text]
122. Alpha-SMA expression in hepatic stellate cells and quantitative analysis of hepatic fibrosis in cirrhosis and in recurrent chronic hepatitis after liver transplantation.
     Dig Liver Dis, 37(5): 349-56. [Abstract] [Full-text]
123. Role of inhaled nitric oxide in adult heart or lung transplant recipients.
     Ann Pharmacother, 39(5): 913-7. [Abstract] [Full-text]
124. Interventions for preventing bone disease in kidney transplant recipients.
     Cochrane Database Syst Rev. [Abstract] [Full-text]
125. Calcium channel blockers for preventing acute tubular necrosis in kidney transplant recipients.
     Cochrane Database Syst Rev. [Abstract] [Full-text]
126. Case report: hepatic artery pseudoaneurysm after liver transplantation: definitive treatment with a stent-graft after failed coil embolisation.
     Br J Radiol, 78(929): 453-6. [Abstract] [Full-text]
127. A randomized, double-blind comparison of lactated Ringer's solution and 0.9% NaCl during renal transplantation.
     Anesth Analg, 100(5): 1518-24, table of contents. [Abstract] [Full-text]
128. A review of aprotinin in orthotopic liver transplantation: can its harmful effects offset its beneficial effects?
     Anesth Analg, 100(5): 1248-55. [Abstract] [Full-text]
129. Relationship between anti-ABO antibody production and hemolytic anemia after minor ABO-mismatched living-donor lobar lung transplantation.
     Transplant Proc, 37(2): 1371-2. [Abstract] [Full-text]
130. Outcome following single vs bilateral lung transplantation in recipients 60 years of age and older.
     Transplant Proc, 37(2): 1369-70. [Abstract] [Full-text]
131. Posttraumatic stress disorder after implantation of a mechanical assist device followed by heart transplantation: evaluation of patients and partners.
     Transplant Proc, 37(2): 1365-8. [Abstract] [Full-text]
132. Primary cardiac lymphoma in a heart transplant recipient.
     Transplant Proc, 37(2): 1362-4. [Abstract] [Full-text]
133. C0h/C2h monitoring of the pharmacodynamics of cyclosporin plus mycophenolate mofetil in human heart transplant recipients.
     Transplant Proc, 37(2): 1360-1. [Abstract] [Full-text]
134. C2 and C0 values for monitoring cyclosporine therapy in stable heart transplant recipients.
     Transplant Proc, 37(2): 1355-9. [Abstract] [Full-text]
135. Chronic renal failure and end-stage renal disease are associated with a high rate of mortality after heart transplantation.
     Transplant Proc, 37(2): 1352-4. [Abstract] [Full-text]
136. Early and late rejection and HLA sensitization at the time of heart transplantation in patients bridged with left ventricular assist devices.
     Transplant Proc, 37(2): 1349-51. [Abstract] [Full-text]
137. Usefulness of pulmonary hypertension reversibility test with sodium nitroprusside in stratification of early death risk after orthotopic heart transplantation.
     Transplant Proc, 37(2): 1346-8. [Abstract] [Full-text]
138. Usefulness of stanford scale of intimal hyperplasia assessed by intravascular ultrasound to predict time of onset and severity of cardiac allograft vasculopathy.
     Transplant Proc, 37(2): 1343-5. [Abstract] [Full-text]
139. Phenylethanolamine N-methyltransferase gene expression in transplanted human heart.
     Transplant Proc, 37(2): 1340-2. [Abstract] [Full-text]
140. Daclizumab is associated with decreased rejection and no increased mortality in cardiac transplant patients receiving MMF, cyclosporine, and corticosteroids.
     Transplant Proc, 37(2): 1333-9. [Abstract] [Full-text]
141. Donor heart selection: Wythenshawe experience.
     Transplant Proc, 37(2): 1331-2. [Abstract] [Full-text]
142. Single-shot antithymocyte globulin (ATG) induction for pancreas/kidney transplantation: ATG-Fresenius versus Thymoglobulin.
     Transplant Proc, 37(2): 1301-4. [Abstract] [Full-text]
143. Incidence of coronary heart disease and cardiac events in patients undergoing kidney and pancreatic transplantation.
     Transplant Proc, 37(2): 1297-300. [Abstract] [Full-text]
144. Pilot study of rapid steroid elimination with alemtuzumab induction therapy in kidney and pancreas transplantation.
     Transplant Proc, 37(2): 1294-6. [Abstract] [Full-text]
145. Surgical nuances in pancreas transplantation.
     Transplant Proc, 37(2): 1291-3. [Abstract] [Full-text]
146. A multicenter analysis of the significance of HLA matching on outcomes after kidney-pancreas transplantation.
     Transplant Proc, 37(2): 1289-90. [Abstract] [Full-text]
147. Pilot study of early corticosteroid elimination after pancreas transplantation.
     Transplant Proc, 37(2): 1287-8. [Abstract] [Full-text]
148. Comparable kidney graft survival of type 1 diabetics treated with simultaneous pancreas-kidney transplantation and nondiabetic patients treated with cadaveric renal transplantation.
     Transplant Proc, 37(2): 1285-6. [Abstract] [Full-text]
149. Simultaneous pancreas-kidney transplants in type I and type II diabetic patients with end-stage renal disease: similar 10-year outcomes.
     Transplant Proc, 37(2): 1283-4. [Abstract] [Full-text]
150. Graft survival and immune regulation of pancreas allograft recipients induced with thymoglobulin, sirolimus, and cyclosporine.
     Transplant Proc, 37(2): 1280-2. [Abstract] [Full-text]
151. Successful solitary pancreas transplantation with portal-enteric drainage following unsuccessful islet cell transplantation.
     Transplant Proc, 37(2): 1278-9. [Abstract] [Full-text]
152. Ninety-five percent insulin independence rate 3 years after pancreas transplantation alone with portal-enteric drainage.
     Transplant Proc, 37(2): 1274-7. [Abstract] [Full-text]
153. Multivariate analysis of the influence of donor and recipient cytomegalovirus sero-pairing on outcomes in simultaneous kidney-pancreas transplantation: the South-Eastern Organ Procurement Foundation Experience.
     Transplant Proc, 37(2): 1271-3. [Abstract] [Full-text]
154. Donors with a maximum body weight of 50 kg for simultaneous pancreas-kidney transplantation.
     Transplant Proc, 37(2): 1268-70. [Abstract] [Full-text]
155. Pancreas transplants from donors aged 45 years or older.
     Transplant Proc, 37(2): 1265-7. [Abstract] [Full-text]
156. University of Wisconsin solution versus Celsior solution in clinical pancreas transplantation.
     Transplant Proc, 37(2): 1262-4. [Abstract] [Full-text]
157. Acceptance criteria of pancreas grafts: how do surgeons decide in Europe?
     Transplant Proc, 37(2): 1259-61. [Abstract] [Full-text]
158. Recurrence rate and transplantability after liver resection in patients with hepatocellular carcinoma who initially met transplantation criteria.
     Transplant Proc, 37(2): 1254-6. [Abstract] [Full-text]
159. Microvascular tumor embolism: independent prognostic factor after liver transplantation in hepatocellular carcinoma.
     Transplant Proc, 37(2): 1251-3. [Abstract] [Full-text]
160. Transjugular intrahepatic portosystemic shunts for refractory ascites after liver transplantation.
     Transplant Proc, 37(2): 1248-50. [Abstract] [Full-text]
161. Comparison between nifedipine and carvedilol in the treatment of de novo arterial hypertension after liver transplantation: preliminary results of a controlled clinical trial.
     Transplant Proc, 37(2): 1245-7. [Abstract] [Full-text]
162. Methicillin-resistant Staphylococcus aureus infection in liver transplantation: a matched controlled study.
     Transplant Proc, 37(2): 1243-4. [Abstract] [Full-text]
163. Review of 31 cases of morphologic hepatitis in liver transplant patients not related to disease recurrence.
     Transplant Proc, 37(2): 1240-2. [Abstract] [Full-text]
164. Risk of transmission of hepatitis B virus from anti-HBC positive cadaveric organ donors: a collaborative study.
     Transplant Proc, 37(2): 1238-9. [Abstract] [Full-text]
165. Genotypic resistance of hepatitis B virus to lamivudine in renal transplant recipients.
     Transplant Proc, 37(2): 1235-7. [Abstract] [Full-text]
166. Interferon combined with cyclosporine treatment as an effective countermeasure against hepatitis C virus recurrence in liver transplant patients with end-stage hepatitis C virus related disease.
     Transplant Proc, 37(2): 1233-4. [Abstract] [Full-text]
167. HHV-6-DNAemia related to CMV-DNAemia after liver transplantation.
     Transplant Proc, 37(2): 1230-2. [Abstract] [Full-text]
168. DNA microarray-based gene expression profiles of cytomegalovirus infection and acute rejection in liver transplants.
     Transplant Proc, 37(2): 1227-9. [Abstract] [Full-text]
169. Infectious complications limit the outcome of liver transplantation in medical urgency code 2 patients.
     Transplant Proc, 37(2): 1224-6. [Abstract] [Full-text]
170. Nephrotoxic effects of immunosuppressant therapy in pediatric liver transplant recipients.
     Transplant Proc, 37(2): 1220-3. [Abstract] [Full-text]
171. Steroid-free induction and preemptive antiviral therapy for liver transplant recipients with hepatitis C: a preliminary report from a prospective randomized study.
     Transplant Proc, 37(2): 1217-9. [Abstract] [Full-text]
172. Preliminary analysis of early outcomes of a prospective, randomized trial of complete steroid avoidance in liver transplantation.
     Transplant Proc, 37(2): 1214-6. [Abstract] [Full-text]
173. Conversion of stable liver transplant recipients from a twice-daily Prograf-based regimen to a once-daily modified release tacrolimus-based regimen.
     Transplant Proc, 37(2): 1211-3. [Abstract] [Full-text]
174. Tacrolimus for primary liver transplantation: 12 to 15 years actual follow-up with safety profile.
     Transplant Proc, 37(2): 1207-10. [Abstract] [Full-text]
175. New strategy for ABO-incompatible living donor liver transplantation with anti-CD20 antibody (rituximab) and plasma exchange.
     Transplant Proc, 37(2): 1205-6. [Abstract] [Full-text]
176. The impact of Campath 1H induction in adult liver allotransplantation.
     Transplant Proc, 37(2): 1203-4. [Abstract] [Full-text]
177. Experience of a successful pediatric liver transplant program in Mexico.
     Transplant Proc, 37(2): 1201-2. [Abstract] [Full-text]
178. Pregnancy and delivery after liver transplantation.
     Transplant Proc, 37(2): 1197-200. [Abstract] [Full-text]
179. Decrease of CD4+CD25+ T cells in peripheral blood after liver transplantation: association with immunosuppression.
     Transplant Proc, 37(2): 1194-6. [Abstract] [Full-text]
180. Livers transplanted from donors after cardiac death occurring in the ICU or the operating room have excellent outcomes.
     Transplant Proc, 37(2): 1188-93. [Abstract] [Full-text]
181. Adult liver transplantation using liver grafts from donors over 70 years of age.
     Transplant Proc, 37(2): 1186-7. [Abstract] [Full-text]
182. Does the liver ever age? Results of liver transplantation with donors above 80 years of age.
     Transplant Proc, 37(2): 1182-5. [Abstract] [Full-text]
183. Liver transplantation using livers from septuagenarian and octogenarian donors: an underused strategy to reduce mortality on the waiting list.
     Transplant Proc, 37(2): 1180-1. [Abstract] [Full-text]
184. Living donor liver transplantation for hepatocellular carcinoma: a special reference to a preoperative des-gamma-carboxy prothrombin value.
     Transplant Proc, 37(2): 1177-9. [Abstract] [Full-text]
185. Orthotopic liver transplantation for alagille syndrome.
     Transplant Proc, 37(2): 1174-6. [Abstract] [Full-text]
186. Long-term outcome of right split in situ grafts in adults.
     Transplant Proc, 37(2): 1170-3. [Abstract] [Full-text]
187. Right hemiliver transplant: results from living and cadaveric donors.
     Transplant Proc, 37(2): 1167-9. [Abstract] [Full-text]
188. Use of extended right grafts from in situ split livers in adult liver transplantation: a comparison with whole-liver transplants.
     Transplant Proc, 37(2): 1164-6. [Abstract] [Full-text]
189. Liver retransplantation: a single-center outcome and financial analysis.
     Transplant Proc, 37(2): 1161-3. [Abstract] [Full-text]
190. Risk factors predicting survival of liver transplantation.
     Transplant Proc, 37(2): 1155-60. [Abstract] [Full-text]
191. Orthotopic liver transplantation for biliary atresia.
     Transplant Proc, 37(2): 1153-4. [Abstract] [Full-text]
192. Daclizumab induction therapy associated with tacrolimus-MMF has better outcome compared with tacrolimus-MMF alone in pediatric living donor liver transplantation.
     Transplant Proc, 37(2): 1151-2. [Abstract] [Full-text]
193. Orthotopic liver transplantation for Byler's disease.
     Transplant Proc, 37(2): 1149-50. [Abstract] [Full-text]
194. Liver transplantation in children weighting less than 6 kg: the Bergamo experience.
     Transplant Proc, 37(2): 1143-5. [Abstract] [Full-text]
195. Early portal vein thrombosis after pediatric split liver transplantation with left lateral segment graft.
     Transplant Proc, 37(2): 1141-2. [Abstract] [Full-text]
196. Portal vein complications in the long-term course after pediatric living donor liver transplantation.
     Transplant Proc, 37(2): 1138-40. [Abstract] [Full-text]
197. Liver transplantation for children: Red Cross Children's Hospital experience.
     Transplant Proc, 37(2): 1134-7. [Abstract] [Full-text]
198. Efficacy of auxiliary partial orthotopic liver transplantation for cure of hemophilia in a canine hemophilia A model.
     Transplant Proc, 37(2): 1131-3. [Abstract] [Full-text]
199. Cost/efficacy clinical trial about the use of T-tube in cadaveric donor liver transplant: preliminary results.
     Transplant Proc, 37(2): 1129-30. [Abstract] [Full-text]
200. Role of choledochojejunostomy in liver transplantation.
     Transplant Proc, 37(2): 1126-8. [Abstract] [Full-text]
201. Transhepatic biliary catheterization before graft implant in living donor liver transplantation.
     Transplant Proc, 37(2): 1124-5. [Abstract] [Full-text]
202. Biliary reconstruction and complications of left lobe living donor liver transplantation.
     Transplant Proc, 37(2): 1122-3. [Abstract] [Full-text]
203. Liver transplantation in recipients with portal vein thrombosis: experience of a single transplant center.
     Transplant Proc, 37(2): 1119-21. [Abstract] [Full-text]
204. A new venous conduit utilizing the recipient portal vein branches for segment V in adult partial liver transplantation.
     Transplant Proc, 37(2): 1117-8. [Abstract] [Full-text]
205. The significance of hepatic vein outflow volume in hepatic outflow insufficiency of living right liver graft evaluated by Doppler ultrasound.
     Transplant Proc, 37(2): 1115-6. [Abstract] [Full-text]
206. Surgical procedures for decompression of excessive shear stress in small-for-size living donor liver transplantation--new hepatic vein reconstruction.
     Transplant Proc, 37(2): 1108-11. [Abstract] [Full-text]
207. Neuropsychological and neurophysiological evaluation in cirrhotic patients with minimal hepatic encephalopathy undergoing liver transplantation.
     Transplant Proc, 37(2): 1104-7. [Abstract] [Full-text]
208. Multiple organ failure caused by end-stage liver disease successfully treated with living donor liver transplantation using perioperative percutaneous cardiopulmonary support: a case report.
     Transplant Proc, 37(2): 1101-3. [Abstract] [Full-text]
209. DR antigens influence graft outcome and HCV recurrence after liver transplantation.
     Transplant Proc, 37(2): 1099-100. [Abstract] [Full-text]
210. Liver transplantation in fulminant hepatic failure: experience with 40 adult patients over a 17-year period.
     Transplant Proc, 37(2): 1085-7. [Abstract] [Full-text]
211. Decision-related factors and attitudes toward donation in living related liver transplantation: ten-year experience.
     Transplant Proc, 37(2): 1081-4. [Abstract] [Full-text]
212. Results of 132 hepatectomies for living donor liver transplantation: report of one death.
     Transplant Proc, 37(2): 1079-80. [Abstract] [Full-text]
213. Domino liver transplantation in living donors.
     Transplant Proc, 37(2): 1076-8. [Abstract] [Full-text]
214. Imaging of hepatic arterial anatomy for depicting vascular variations in living related liver transplant donor candidates with multidetector computed tomography: comparison with conventional angiography.
     Transplant Proc, 37(2): 1070-3. [Abstract] [Full-text]
215. Anatomic variation of the right hepatic artery and its reconstruction for living donor liver transplantation using right lobe graft.
     Transplant Proc, 37(2): 1067-9. [Abstract] [Full-text]
216. The main hepatic anatomic variations for the purpose of split-liver transplantation.
     Transplant Proc, 37(2): 1063-6. [Abstract] [Full-text]
217. Computerized CT-based 3D visualization technique in living related liver transplantation.
     Transplant Proc, 37(2): 1059-62. [Abstract] [Full-text]
218. Ureteric complications of renal transplantation: the impact of the double J stent and the anterior extravesical ureteroneocystostomy.
     Transplant Proc, 37(2): 1054-6. [Abstract] [Full-text]
219. Effect of routine insertion of a double-J stent after living related renal transplantation.
     Transplant Proc, 37(2): 1052-3. [Abstract] [Full-text]
220. Renovascular reconstruction of grafts with renal artery variations in living kidney transplantation.
     Transplant Proc, 37(2): 1049-51. [Abstract] [Full-text]
221. Efficacy and safety of Palmaz stent implantation in the treatment of renal artery stenosis in renal transplantation.
     Transplant Proc, 37(2): 1047-8. [Abstract] [Full-text]
222. A simple cardiovascular risk score can predict poor outcome in non-heart-beating donor renal transplantation.
     Transplant Proc, 37(2): 1044-6. [Abstract] [Full-text]
223. Cardiovascular effects of successful renal transplantation: a 30-month study on left ventricular morphology, systolic and diastolic functions.
     Transplant Proc, 37(2): 1039-43. [Abstract] [Full-text]
224. Cyclosporine and tacrolimus: influence on cardiovascular risk factors.
     Transplant Proc, 37(2): 1036-8. [Abstract] [Full-text]
225. Treatment of hypercholesterolemia with ezetimibe in the kidney transplant population.
     Transplant Proc, 37(2): 1033-5. [Abstract] [Full-text]
226. Weight gain after living-related renal transplantation affects long-term graft function.
     Transplant Proc, 37(2): 1029-32. [Abstract] [Full-text]
227. Increased risk of hemorrhagic complications in renal allograft recipients receiving systemic heparin early posttransplantation.
     Transplant Proc, 37(2): 1026-8. [Abstract] [Full-text]
228. Influence of vitamin D receptor gene polymorphisms on secondary hyperparathyroidism and bone density after kidney transplantation.
     Transplant Proc, 37(2): 1023-5. [Abstract] [Full-text]
229. Evaluation of cortical bone by peripheral quantitative computed tomography in renal transplant recipients.
     Transplant Proc, 37(2): 1020-2. [Abstract] [Full-text]
230. Changes in bone mineral density and selected metabolic parameters over 24 months following renal transplantation.
     Transplant Proc, 37(2): 1014-9. [Abstract] [Full-text]
231. Influence of angiotensin-converting enzyme polymorphism gene, IGF-1, and other factors in the response rate of hematocrit to enalapril treatment in patients with posttransplant erythrocytosis.
     Transplant Proc, 37(2): 1012-3. [Abstract] [Full-text]
232. Predictive factors of postrenal transplant anemia.
     Transplant Proc, 37(2): 1009-11. [Abstract] [Full-text]
233. Iron deficiency--an underrecognized problem in nonanemic and erythrocytic kidney transplant recipients: risks and effects of ACEI and of iron treatment.
     Transplant Proc, 37(2): 1007-8. [Abstract] [Full-text]
234. Are anemic patients more sensitive to calcineurin inhibitors?
     Transplant Proc, 37(2): 1005-6. [Abstract] [Full-text]
235. Prospective, multicenter, randomized trial to compare incidence of new-onset diabetes mellitus and glucose metabolism in patients receiving cyclosporine microemulsion versus tacrolimus after de novo kidney transplantation.
     Transplant Proc, 37(2): 1001-4. [Abstract] [Full-text]
236. Immediate conversion from tacrolimus to cyclosporine in the treatment of posttransplantation diabetes mellitus.
     Transplant Proc, 37(2): 999-1000. [Abstract] [Full-text]
237. Blood pressure and graft outcome in renal transplantation.
     Transplant Proc, 37(2): 997-8. [Abstract] [Full-text]
238. Inhibition of plasminogen activator inhibitor-1 by angiotensin II receptor blockers on cyclosporine-treated renal allograft recipients.
     Transplant Proc, 37(2): 994-6. [Abstract] [Full-text]
239. Renoprotective effect of early inhibition of the renin-angiotensin system in renal transplant recipients.
     Transplant Proc, 37(2): 991-3. [Abstract] [Full-text]
240. Tubular and glomerular proteinuria in diagnosing chronic allograft nephropathy with relevance to the degree of urinary albumin excretion.
     Transplant Proc, 37(2): 987-90. [Abstract] [Full-text]
241. Analysis of allograft biopsy specimens in renal transplants with proteinuria: is proteinuria a culprit of graft loss?
     Transplant Proc, 37(2): 984-6. [Abstract] [Full-text]
242. Loss of peritubular capillaries in the development of chronic allograft nephropathy.
     Transplant Proc, 37(2): 981-3. [Abstract] [Full-text]
243. Hypothesis: epithelial-to-mesenchymal transition is a common cause of chronic allograft failure.
     Transplant Proc, 37(2): 977-80. [Abstract] [Full-text]
244. Parathyroidectomy for parathyroid carcinoma in renal transplantation.
     Transplant Proc, 37(2): 973-6. [Abstract] [Full-text]
245. Mutation scanning of the p53 tumor suppressor gene in renal and liver transplant patients in Hungary.
     Transplant Proc, 37(2): 969-72. [Abstract] [Full-text]
246. Kaposi's sarcoma in renal transplant patients: predisposing factors and prognosis.
     Transplant Proc, 37(2): 967-8. [Abstract] [Full-text]
247. Regression of Kaposi's sarcoma in renal graft recipients after conversion to sirolimus treatment.
     Transplant Proc, 37(2): 964-6. [Abstract] [Full-text]
248. Prostate cancer prior to solid organ transplantation: the Israel Penn International Transplant Tumor Registry experience.
     Transplant Proc, 37(2): 958-9. [Abstract] [Full-text]
249. Chemotherapy for posttransplant lymphoproliferative disorder: the Israel Penn International Transplant Tumor Registry experience.
     Transplant Proc, 37(2): 956-7. [Abstract] [Full-text]
250. Posttransplant lymphoproliferative disorder: significance of central nervous system involvement.
     Transplant Proc, 37(2): 954-5. [Abstract] [Full-text]
251. Successful vaccination against varicella zoster virus prior to kidney transplantation.
     Transplant Proc, 37(2): 952-3. [Abstract] [Full-text]
252. Treatment of cytomegalovirus infection or disease in solid organ transplant recipients with valganciclovir.
     Transplant Proc, 37(2): 949-51. [Abstract] [Full-text]
253. Polyoma BK virus reactivation in kidney and pancreas-kidney recipients.
     Transplant Proc, 37(2): 947-8. [Abstract] [Full-text]
254. Human polyoma virus in kidney transplants: SV40 T-antigen demonstration in the urine.
     Transplant Proc, 37(2): 945-6. [Abstract] [Full-text]
255. Outcomes of patients with rejection post-polyomavirus nephropathy.
     Transplant Proc, 37(2): 942-4. [Abstract] [Full-text]
256. Natural history of hepatitis C virus infection in adult renal graft recipients.
     Transplant Proc, 37(2): 940-1. [Abstract] [Full-text]
257. Mycobacterial infections after kidney transplant.
     Transplant Proc, 37(2): 937-9. [Abstract] [Full-text]
258. Fungal infections in transplant recipients receiving alemtuzumab.
     Transplant Proc, 37(2): 934-6. [Abstract] [Full-text]
259. Combined therapy of deoxyspergualin and plasmapheresis: a useful treatment for antibody-mediated acute rejection after kidney transplantation.
     Transplant Proc, 37(2): 930-3. [Abstract] [Full-text]
260. Deoxyspergualin prophylaxis with tacrolimus further improves long-term graft survival in living-related renal-transplant recipients transfused with donor-specific blood.
     Transplant Proc, 37(2): 927-9. [Abstract] [Full-text]
261. Reversal of acute cellular rejection after renal transplantation with Campath-1H.
     Transplant Proc, 37(2): 923-6. [Abstract] [Full-text]
262. Assessment of two strategies of neoral administration, early versus delayed, on renal function and efficacy in de novo renal transplant patients receiving myfortic, steroids, and anti-IL2R antibodies: 12-month results of a randomized, multicentre, open, prospective controlled study.
     Transplant Proc, 37(2): 920-2. [Abstract] [Full-text]
263. Safety assessment of the conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in stable renal transplant recipients.
     Transplant Proc, 37(2): 916-9. [Abstract] [Full-text]
264. Safety and efficacy after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium: results of a 1-year extension study.
     Transplant Proc, 37(2): 912-5. [Abstract] [Full-text]
265. Long-term administration of enteric-coated mycophenolate sodium in kidney transplant patients.
     Transplant Proc, 37(2): 909-11. [Abstract] [Full-text]
266. No-load sirolimus with tacrolimus and steroids is safe and effective in renal transplantation.
     Transplant Proc, 37(2): 906-8. [Abstract] [Full-text]
267. Basiliximab (Simulect) reduces acute rejection among sensitized kidney allograft recipients.
     Transplant Proc, 37(2): 903-5. [Abstract] [Full-text]
268. Limited-dose Daclizumab versus Basiliximab: a comparison of cost and efficacy in preventing acute rejection.
     Transplant Proc, 37(2): 899-902. [Abstract] [Full-text]
269. Cyclosporine-sparing effect of basiliximab in renal transplant recipients with mycophenolate mofetil.
     Transplant Proc, 37(2): 895-8. [Abstract] [Full-text]
270. Comparison of induction based on continuous vs discontinuous administration of antithymocyte globulins in renal transplant patients: efficacy and long-term safety.
     Transplant Proc, 37(2): 892-4. [Abstract] [Full-text]
271. Multivariate analysis of antibody induction therapy and their associated outcomes in deceased donor transplants.
     Transplant Proc, 37(2): 889-91. [Abstract] [Full-text]
272. Multivariate analysis of the effectiveness of using antibody induction therapy according to the degree of HLA mismatches.
     Transplant Proc, 37(2): 886-8. [Abstract] [Full-text]
273. The safety and efficacy of early withdrawal of calcineurin inhibitors in kidney transplant recipients 6 months' posttransplant.
     Transplant Proc, 37(2): 884-5. [Abstract] [Full-text]
274. Excellent results with calcineurin inhibitor-free initial immunosuppression in old recipients of old kidneys.
     Transplant Proc, 37(2): 881-3. [Abstract] [Full-text]
275. The effect of urinary protein excretion in post-renal transplant recurrent nephrotic syndrome on basiliximab pharmacokinetics and pharmacodynamics in a pediatric patient.
     Transplant Proc, 37(2): 879-80. [Abstract] [Full-text]
276. Sequential blood level monitoring of basiliximab during multisession plasmapheresis in a kidney transplant recipient.
     Transplant Proc, 37(2): 875-8. [Abstract] [Full-text]</